Drug Trial Radar · NCT03071341
Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I
Last checked: Nov 20, 2026Latest source record: Mar 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Oct 2016
Primary completion
Feb 1, 2018
Study completion Feb 1, 2018
Sponsor
- Lead sponsor
- ArmaGen, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AGT-181 is a fusion protein containing alpha-L-iduronidase that is intended to deliver the enzyme peripherally and to the brain, when administered intravenously. This is a long term safety and tolerability study of AGT-181 in patients with MPS I who completed the previous 26-week study, AGT-181-101. Information on the biological activity of the investigational drug will also be collected.
Conditions
- Mucopolysaccharidosis I
Interventions
AGT-181Drug
Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
Primary outcomes
What the sponsor says the trial is designed to measure.
- number of patients with adverse events as a measure of safety and tolerabilityTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
HCPA - Hospital das Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.